Literature DB >> 23296110

Brain cancer in 2012: Molecular characterization leads the way.

Roger Stupp1, Monika E Hegi.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 23296110     DOI： 10.1038/nrclinonc.2012.240

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  8 in total

1.  Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial.

Authors:  Annika Malmström; Bjørn Henning Grønberg; Christine Marosi; Roger Stupp; Didier Frappaz; Henrik Schultz; Ufuk Abacioglu; Björn Tavelin; Benoit Lhermitte; Monika E Hegi; Johan Rosell; Roger Henriksson
Journal:  Lancet Oncol       Date:  2012-08-08       Impact factor: 41.316

2.  NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality.

Authors:  Roger Stupp; Eric T Wong; Andrew A Kanner; David Steinberg; Herbert Engelhard; Volkmar Heidecke; Eilon D Kirson; Sophie Taillibert; Frank Liebermann; Vladimir Dbalý; Zvi Ram; J Lee Villano; Nikolai Rainov; Uri Weinberg; David Schiff; Lara Kunschner; Jeffrey Raizer; Jerome Honnorat; Andrew Sloan; Mark Malkin; Joseph C Landolfi; Franz Payer; Maximilian Mehdorn; Robert J Weil; Susan C Pannullo; Manfred Westphal; Martin Smrcka; Lawrence Chin; Herwig Kostron; Silvia Hofer; Jeffrey Bruce; Rees Cosgrove; Nina Paleologous; Yoram Palti; Philip H Gutin
Journal:  Eur J Cancer       Date:  2012-05-18       Impact factor: 9.162

3.  Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951.

Authors:  Martin J van den Bent; Alba A Brandes; Martin J B Taphoorn; Johan M Kros; Mathilde C M Kouwenhoven; Jean-Yves Delattre; Hans J J A Bernsen; Marc Frenay; Cees C Tijssen; Wolfgang Grisold; László Sipos; Roelien H Enting; Pim J French; Winand N M Dinjens; Charles J Vecht; Anouk Allgeier; Denis Lacombe; Thierry Gorlia; Khê Hoang-Xuan
Journal:  J Clin Oncol       Date:  2012-10-15       Impact factor: 44.544

Review 4.  The clinical implications of medulloblastoma subgroups.

Authors:  Paul A Northcott; Andrey Korshunov; Stefan M Pfister; Michael D Taylor
Journal:  Nat Rev Neurol       Date:  2012-05-08       Impact factor: 42.937

5.  Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802.

Authors:  Edward G Shaw; Meihua Wang; Stephen W Coons; David G Brachman; Jan C Buckner; Keith J Stelzer; Geoffrey R Barger; Paul D Brown; Mark R Gilbert; Minesh P Mehta
Journal:  J Clin Oncol       Date:  2012-07-30       Impact factor: 44.544

6.  Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial.

Authors:  Wolfgang Wick; Michael Platten; Christoph Meisner; Jörg Felsberg; Ghazaleh Tabatabai; Matthias Simon; Guido Nikkhah; Kirsten Papsdorf; Joachim P Steinbach; Michael Sabel; Stephanie E Combs; Jan Vesper; Christian Braun; Jürgen Meixensberger; Ralf Ketter; Regine Mayer-Steinacker; Guido Reifenberger; Michael Weller
Journal:  Lancet Oncol       Date:  2012-05-10       Impact factor: 41.316

7.  Novel mutations target distinct subgroups of medulloblastoma.

Authors:  Giles Robinson; Matthew Parker; Tanya A Kranenburg; Charles Lu; Xiang Chen; Li Ding; Timothy N Phoenix; Erin Hedlund; Lei Wei; Xiaoyan Zhu; Nader Chalhoub; Suzanne J Baker; Robert Huether; Richard Kriwacki; Natasha Curley; Radhika Thiruvenkatam; Jianmin Wang; Gang Wu; Michael Rusch; Xin Hong; Jared Becksfort; Pankaj Gupta; Jing Ma; John Easton; Bhavin Vadodaria; Arzu Onar-Thomas; Tong Lin; Shaoyi Li; Stanley Pounds; Steven Paugh; David Zhao; Daisuke Kawauchi; Martine F Roussel; David Finkelstein; David W Ellison; Ching C Lau; Eric Bouffet; Tim Hassall; Sridharan Gururangan; Richard Cohn; Robert S Fulton; Lucinda L Fulton; David J Dooling; Kerri Ochoa; Amar Gajjar; Elaine R Mardis; Richard K Wilson; James R Downing; Jinghui Zhang; Richard J Gilbertson
Journal:  Nature       Date:  2012-08-02       Impact factor: 49.962

8.  2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas.

Authors:  Changho Choi; Sandeep K Ganji; Ralph J DeBerardinis; Kimmo J Hatanpaa; Dinesh Rakheja; Zoltan Kovacs; Xiao-Li Yang; Tomoyuki Mashimo; Jack M Raisanen; Isaac Marin-Valencia; Juan M Pascual; Christopher J Madden; Bruce E Mickey; Craig R Malloy; Robert M Bachoo; Elizabeth A Maher
Journal:  Nat Med       Date:  2012-01-26       Impact factor: 53.440
  8 in total
  6 in total

1.  MPPED2 is downregulated in glioblastoma, and its restoration inhibits proliferation and increases the sensitivity to temozolomide of glioblastoma cells.

Authors:  Simona Pellecchia; Marco De Martino; Francesco Esposito; Cristina Quintavalle; Alfredo Fusco; Pierlorenzo Pallante
Journal:  Cell Cycle       Date:  2021-03-18       Impact factor: 4.534

2.  Hematopoietic stem cells as a tool for the treatment of glioblastoma multiforme.

Authors:  Igor S Bryukhovetskiy; Inessa V Dyuizen; Valeriy E Shevchenko; Andrey S Bryukhovetskiy; Polina V Mischenko; Elena V Milkina; Yuri S Khotimchenko
Journal:  Mol Med Rep       Date:  2016-10-13       Impact factor: 2.952

Review 3.  The Molecular and Microenvironmental Landscape of Glioblastomas: Implications for the Novel Treatment Choices.

Authors:  Federica Di Cintio; Michele Dal Bo; Lorena Baboci; Elena De Mattia; Maurizio Polano; Giuseppe Toffoli
Journal:  Front Neurosci       Date:  2020-11-25       Impact factor: 4.677

4.  Mir-21-Sox2 Axis Delineates Glioblastoma Subtypes with Prognostic Impact.

Authors:  Pratheesh Sathyan; Pascal O Zinn; Anantha L Marisetty; Bin Liu; Mohamed Mostafa Kamal; Sanjay K Singh; Pierre Bady; Li Lu; Khalida M Wani; Bethany L Veo; Joy Gumin; Dina Hamada Kassem; Frederick Robinson; Connie Weng; Veerabhadran Baladandayuthapani; Dima Suki; Howard Colman; Krishna P Bhat; Erik P Sulman; Ken Aldape; Rivka R Colen; Roel G W Verhaak; Zhimin Lu; Gregory N Fuller; Suyun Huang; Frederick F Lang; Raymond Sawaya; Monika Hegi; Sadhan Majumder
Journal:  J Neurosci       Date:  2015-11-11       Impact factor: 6.167

5.  MiR-221/222 target the DNA methyltransferase MGMT in glioma cells.

Authors:  Cristina Quintavalle; Davide Mangani; Giuseppina Roscigno; Giulia Romano; Angel Diaz-Lagares; Margherita Iaboni; Elvira Donnarumma; Danilo Fiore; Pasqualino De Marinis; Ylermi Soini; Manel Esteller; Gerolama Condorelli
Journal:  PLoS One       Date:  2013-09-19       Impact factor: 3.240

6.  miR-29c contribute to glioma cells temozolomide sensitivity by targeting O6-methylguanine-DNA methyltransferases indirectely.

Authors:  Songhua Xiao; Zhen Yang; Xingsheng Qiu; Ruiyan Lv; Jun Liu; Ming Wu; Yiwei Liao; Qing Liu
Journal:  Oncotarget       Date:  2016-08-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.